

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

东曜药业

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1875)

VOLUNTARY ANNOUNCEMENT

LISTING OF CLINICAL RESEARCH AND COMMERCIALIZATION PROJECT IN RELATION TO TAB014 AS A SPECIAL MAJOR PROJECT FOR TECHNOLOGIES OF INNOVATIVE MANUFACTURING OF MAJOR NEW DRUGS IN CHINA

This announcement is made by TOT BIOPHARM International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on January 2, 2020, the Group was notified by the Development Center for Medical Science & Technology of the National Health Commission (國家衛生健康委醫藥衛生科技發展研究中心) of the People’s Republic of China (“**China**”) that its clinical research and commercialization project in relation to TAB014 had been listed as a special major project for technologies of innovative manufacturing of major new drugs (重大新藥創製科技重大專項).

The Board believes that this recognition demonstrates the Group’s strength in the development of innovative drugs. As an anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF mAb), TAB014 is a bevacizumab based antibody for the treatment of retinal neovascularization, such as wet age-related macular degeneration (wAMD). With a wide range of applications, TAB014 may also be used for the treatment of diabetic macular edema (DME), retinal vein occlusion (RVO) and choroidal neovascularization (CNV). TAB014 is registered as a Category 1 new drug in China having enrolled patients in Phase I clinical trial.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, TAB014 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the securities of the Company.

By order of the Board
TOT BIOPHARM International Company Limited
Yeh-Huang, Chun-Ying
Executive Director

Hong Kong, January 2, 2020

As at the date of this announcement, the executive directors of the Company are Ms. Yeh-Huang, Chun-Ying and Dr. Liu, Jun; the non-executive directors of the Company are Mr. Fu, Shan, Dr. Kung, Frank Fang-Chien, Mr. Kang, Pei and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Dr. Sun, Lijun Richard and Mr. Chang, Hong-Jen.